Literature DB >> 24714772

Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.

Guillemette Fouquet1, Stéphanie Guidez1, Charles Herbaux1, Zoé Van de Wyngaert1, Sarah Bonnet1, David Beauvais1, Hélène Demarquette1, Salim Adib1, Bénédicte Hivert1, Mathieu Wemeau1, Céline Berthon1, Louis Terriou1, Valérie Coiteux1, Margaret Macro1, Olivier Decaux1, Thierry Facon1, Damien Huglo1, Xavier Leleu2.   

Abstract

PURPOSE: Solitary plasmacytoma (SP) is a localized proliferation of monoclonal plasma cells in either bone or soft tissue, without evidence of multiple myeloma (MM), and whose prognosis is marked by a high risk of transformation to MM. EXPERIMENTAL
DESIGN: We studied the impact of FDG-PET/CT (2[18F]fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography) on the risk of transformation of SP to overt MM among other markers in a series of 43 patients diagnosed with SP.
RESULTS: Median age was 57.5 years; 48% of patients had an abnormal involved serum-free light chain (sFLC) value, and 64% had an abnormal sFLC ratio at diagnosis. Thirty-three percent had two or more hypermetabolic lesions on initial PET/CT, and 20% had two or more focal lesions on initial MRI. With a median follow-up of 50 months, 14 patients transformed to MM with a median time (TTMM) of 71 months. The risk factors that significantly shortened TTMM at diagnosis were two or more hypermetabolic lesions on PET/CT, abnormal sFLC ratio and involved sFLC, and to a lesser extent at completion of treatment, absence of normalized involved sFLC and PET/CT or MRI. In a multivariate analysis, abnormal initial involved sFLC [OR = 10; 95% confidence interval (CI), 1-87; P = 0.008] and PET/CT (OR = 5; 95% CI, 0-9; P = 0.032) independently shortened TTMM.
CONCLUSIONS: An abnormal involved sFLC value and the presence of at least two hypermetabolic lesions on PET/CT at diagnosis of SP were the two predictors of early evolution to myeloma in our series. This data analysis will need confirmation in a larger study, and the study of these two risk factors may lead to a different management of patients with SP in the future. . ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24714772     DOI: 10.1158/1078-0432.CCR-13-2910

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

Review 1.  Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Authors:  Gary A Ulaner; C Ola Landgren
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

2.  Solitary bone plasmacytomas need to flow.

Authors:  Meletios A Dimopoulos; Evangelos Terpos
Journal:  Blood       Date:  2014-08-21       Impact factor: 22.113

3.  18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.

Authors:  Domenico Albano; Giovanni Bosio; Giorgio Treglia; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-19       Impact factor: 9.236

Review 4.  How We Manage Patients with Plasmacytomas.

Authors:  Despina Fotiou; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 5.  Role of FDG PET in the staging of multiple myeloma.

Authors:  Joao R T Vicentini; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2021-04-04       Impact factor: 2.199

6.  Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients.

Authors:  Yannick Silva; Jean-Marc Riedinger; Marie-Lorraine Chrétien; Denis Caillot; Jill Corre; Kévin Guillen; Alexandre Cochet; Claire Tabouret-Viaud; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-10

Review 7.  Imaging in myeloma with focus on advanced imaging techniques.

Authors:  Tara Barwick; Laure Bretsztajn; Kathryn Wallitt; Dimitri Amiras; Andrea Rockall; Christina Messiou
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

8.  New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.

Authors:  Charles Mesguich; Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

Review 9.  Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Authors:  J Caers; B Paiva; E Zamagni; X Leleu; J Bladé; S Y Kristinsson; C Touzeau; N Abildgaard; E Terpos; R Heusschen; E Ocio; M Delforge; O Sezer; M Beksac; H Ludwig; G Merlini; P Moreau; S Zweegman; M Engelhardt; L Rosiñol
Journal:  J Hematol Oncol       Date:  2018-01-16       Impact factor: 17.388

Review 10.  Solitary Plasmacytoma.

Authors:  Sara Grammatico; Emilia Scalzulli; Maria Teresa Petrucci
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-08-23       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.